NRx Pharmaceuticals Reports Q2 Earnings, Updates on Ketamir-2 Trial
ByAinvest
Friday, Aug 22, 2025 2:18 pm ET1min read
MIRA--
NRXP--
NRx Pharmaceuticals reported a Q2 loss per share of (98c), compared to (75c) YoY. The company has $2.9M in cash and believes it will support operations into 2026 and reach expected regulatory inflection points. CEO Jonathan Javitts highlighted progress with the company's lead programs and the attraction of a group of fundamental biotechnology investors. MIRA Pharmaceuticals completed the Single Ascending Dose portion of its Phase 1 clinical trial for oral Ketamir-2, demonstrating a favorable safety and tolerability profile.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet